Arrowhead Pharmaceuticals (ARWR) Invested Capital (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 5 years of Invested Capital data on file, last reported at $40.0 million in Q1 2026.

• Quarterly Invested Capital fell 38.46% year-over-year to $40.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.0 million (up 140.15% YoY) and the FY2025 annual result came in at $40.0 million, changed N/A from the prior year.
• Invested Capital steadied at $40.0 million in Q1 2026, from $40.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $65.0 million in Q1 2025 to a low of $1.6 million in Q4 2024.
• A 3-year average of $37.8 million and a median of $40.0 million in 2025 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2025 — Invested Capital surged 2361.54% — and 2026, when it slumped 38.46%.
• Tracing ARWR's Invested Capital over 3 years: stood at $1.6 million in 2024, then surged by 2361.54% to $40.0 million in 2025, then changed by 0.0% to $40.0 million in 2026.
• The last three Invested Capital figures came in at $40.0 million (Q1 2026), $40.0 million (Q4 2025), and $40.0 million (Q3 2025), per Business Quant data.